vs
Rollins, Inc.（ROL）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是Royalty Pharma plc的1.5倍（$906.4M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 11.9%，领先22.5%），Rollins, Inc.同比增速更快（10.2% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 0.8%）
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ROL vs RPRX — 直观对比
营收规模更大
ROL
是对方的1.5倍
$622.0M
营收增速更快
ROL
高出5.4%
4.8%
净利率更高
RPRX
高出22.5%
11.9%
两年增速更快
RPRX
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $906.4M | $622.0M |
| 净利润 | $107.8M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 16.1% | 62.4% |
| 净利率 | 11.9% | 34.4% |
| 营收同比 | 10.2% | 4.8% |
| 净利润同比 | 2.5% | 2.9% |
| 每股收益（稀释后） | $0.22 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ROLRPRX
| Q1 26 | $906.4M | — | ||
| Q4 25 | $912.9M | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $999.5M | $578.7M | ||
| Q1 25 | $822.5M | $568.2M | ||
| Q4 24 | $832.2M | $593.6M | ||
| Q3 24 | $916.3M | $564.7M | ||
| Q2 24 | $891.9M | $537.3M |
净利润ROLRPRX
| Q1 26 | $107.8M | — | ||
| Q4 25 | $116.4M | $214.2M | ||
| Q3 25 | $163.5M | $288.2M | ||
| Q2 25 | $141.5M | $30.2M | ||
| Q1 25 | $105.2M | $238.3M | ||
| Q4 24 | $105.7M | $208.2M | ||
| Q3 24 | $136.9M | $544.0M | ||
| Q2 24 | $129.4M | $102.0M |
营业利润率ROLRPRX
| Q1 26 | 16.1% | — | ||
| Q4 25 | 17.5% | 62.4% | ||
| Q3 25 | 21.9% | 70.1% | ||
| Q2 25 | 19.8% | 36.3% | ||
| Q1 25 | 17.3% | 94.0% | ||
| Q4 24 | 18.1% | 60.9% | ||
| Q3 24 | 20.9% | — | ||
| Q2 24 | 20.4% | 50.2% |
净利率ROLRPRX
| Q1 26 | 11.9% | — | ||
| Q4 25 | 12.8% | 34.4% | ||
| Q3 25 | 15.9% | 47.3% | ||
| Q2 25 | 14.2% | 5.2% | ||
| Q1 25 | 12.8% | 41.9% | ||
| Q4 24 | 12.7% | 35.1% | ||
| Q3 24 | 14.9% | 96.3% | ||
| Q2 24 | 14.5% | 19.0% |
每股收益（稀释后）ROLRPRX
| Q1 26 | $0.22 | — | ||
| Q4 25 | $0.24 | $0.49 | ||
| Q3 25 | $0.34 | $0.67 | ||
| Q2 25 | $0.29 | $0.07 | ||
| Q1 25 | $0.22 | $0.55 | ||
| Q4 24 | $0.22 | $0.46 | ||
| Q3 24 | $0.28 | $1.21 | ||
| Q2 24 | $0.27 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $116.5M | $618.7M |
| 总债务越低越好 | $650.6M | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $3.2B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.47× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ROLRPRX
| Q1 26 | $116.5M | — | ||
| Q4 25 | $100.0M | $618.7M | ||
| Q3 25 | $127.4M | $938.9M | ||
| Q2 25 | $123.0M | $631.9M | ||
| Q1 25 | $201.2M | $1.1B | ||
| Q4 24 | $89.6M | $929.0M | ||
| Q3 24 | $95.3M | $950.1M | ||
| Q2 24 | $106.7M | $1.8B |
总债务ROLRPRX
| Q1 26 | $650.6M | — | ||
| Q4 25 | $486.1M | $9.0B | ||
| Q3 25 | $485.7M | $8.9B | ||
| Q2 25 | $485.3M | $8.0B | ||
| Q1 25 | $485.5M | $7.6B | ||
| Q4 24 | $395.3M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益ROLRPRX
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.5B | $9.6B | ||
| Q2 25 | $1.4B | $9.5B | ||
| Q1 25 | $1.4B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
总资产ROLRPRX
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | $19.6B | ||
| Q3 25 | $3.2B | $19.3B | ||
| Q2 25 | $3.2B | $18.3B | ||
| Q1 25 | $2.9B | $17.6B | ||
| Q4 24 | $2.8B | $18.2B | ||
| Q3 24 | $2.8B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B |
负债/权益比ROLRPRX
| Q1 26 | 0.47× | — | ||
| Q4 25 | 0.35× | 0.92× | ||
| Q3 25 | 0.32× | 0.93× | ||
| Q2 25 | 0.34× | 0.84× | ||
| Q1 25 | 0.36× | 0.78× | ||
| Q4 24 | 0.30× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $118.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $111.2M | — |
| 自由现金流率自由现金流/营收 | 12.3% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $621.1M | — |
8季度趋势，按日历期对齐
经营现金流ROLRPRX
| Q1 26 | $118.4M | — | ||
| Q4 25 | $164.7M | $827.1M | ||
| Q3 25 | $191.3M | $702.6M | ||
| Q2 25 | $175.1M | $364.0M | ||
| Q1 25 | $146.9M | $596.1M | ||
| Q4 24 | $188.2M | $742.5M | ||
| Q3 24 | $146.9M | $703.6M | ||
| Q2 24 | $145.1M | $658.2M |
自由现金流ROLRPRX
| Q1 26 | $111.2M | — | ||
| Q4 25 | $159.0M | — | ||
| Q3 25 | $182.8M | — | ||
| Q2 25 | $168.0M | — | ||
| Q1 25 | $140.1M | — | ||
| Q4 24 | $184.0M | — | ||
| Q3 24 | $139.4M | — | ||
| Q2 24 | $136.4M | — |
自由现金流率ROLRPRX
| Q1 26 | 12.3% | — | ||
| Q4 25 | 17.4% | — | ||
| Q3 25 | 17.8% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 17.0% | — | ||
| Q4 24 | 22.1% | — | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 15.3% | — |
资本支出强度ROLRPRX
| Q1 26 | 0.8% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 1.0% | — |
现金转化率ROLRPRX
| Q1 26 | 1.10× | — | ||
| Q4 25 | 1.41× | 3.86× | ||
| Q3 25 | 1.17× | 2.44× | ||
| Q2 25 | 1.24× | 12.06× | ||
| Q1 25 | 1.40× | 2.50× | ||
| Q4 24 | 1.78× | 3.57× | ||
| Q3 24 | 1.07× | 1.29× | ||
| Q2 24 | 1.12× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ROL
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
